JP2025069166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025069166A5 JP2025069166A5 JP2025003479A JP2025003479A JP2025069166A5 JP 2025069166 A5 JP2025069166 A5 JP 2025069166A5 JP 2025003479 A JP2025003479 A JP 2025003479A JP 2025003479 A JP2025003479 A JP 2025003479A JP 2025069166 A5 JP2025069166 A5 JP 2025069166A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- set forth
- sequence set
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902344A AU2019902344A0 (en) | 2019-07-02 | Antibodies | |
| AU2019902344 | 2019-07-02 | ||
| JP2021578269A JP7678769B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
| PCT/AU2020/050690 WO2021000018A1 (en) | 2019-07-02 | 2020-07-02 | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578269A Division JP7678769B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025069166A JP2025069166A (ja) | 2025-04-30 |
| JP2025069166A5 true JP2025069166A5 (enExample) | 2025-05-23 |
Family
ID=74100117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578269A Active JP7678769B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
| JP2025003479A Pending JP2025069166A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578269A Active JP7678769B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220323619A1 (enExample) |
| EP (1) | EP3994177A4 (enExample) |
| JP (2) | JP7678769B2 (enExample) |
| KR (1) | KR20220057517A (enExample) |
| CN (1) | CN114555641A (enExample) |
| AU (1) | AU2020299025A1 (enExample) |
| BR (1) | BR112021026663A2 (enExample) |
| CA (1) | CA3141471A1 (enExample) |
| CL (1) | CL2021003563A1 (enExample) |
| IL (1) | IL289523A (enExample) |
| MA (1) | MA56469A (enExample) |
| MX (1) | MX2021015669A (enExample) |
| WO (1) | WO2021000018A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11878312B2 (en) * | 2011-11-21 | 2024-01-23 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| US12350686B2 (en) * | 2011-11-21 | 2025-07-08 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| US11957998B2 (en) * | 2019-06-06 | 2024-04-16 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| EP4294845A4 (en) * | 2021-02-22 | 2026-01-07 | Abdera Therapeutics Inc | Immunoconjugates for targeted radioisotope therapy |
| US20240359144A1 (en) * | 2021-09-01 | 2024-10-31 | Telix Pharmaceuticals (Innovations) Pty Ltd | Aggregate separation method |
| EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
| RS67935B1 (sr) | 2022-05-17 | 2026-04-30 | Bayer Ag | Radiofarmaceutski kompleksi koji ciljaju na prostata-specifični membranski antigen i njihove kombinacije |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| JP2026510493A (ja) * | 2023-03-09 | 2026-04-07 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 多機能抗体 |
| WO2024207070A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Methods of treating cancers expressing pdgfralpha |
| WO2024207069A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Reagents and methods for imaging cancers expressing pdgfralpha |
| KR20250175319A (ko) * | 2023-04-04 | 2025-12-16 | 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 | Pdgfr알파를 발현하는 암을 치료하는 방법 |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| TW202611088A (zh) | 2024-07-23 | 2026-03-16 | 美商雅博得樂醫療公司 | 5t4結合多肽及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1979379B1 (en) * | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| CA2766409C (en) * | 2009-07-03 | 2023-04-25 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| CA3040276A1 (en) * | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| KR20210090298A (ko) * | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| TW201920285A (zh) * | 2013-04-29 | 2019-06-01 | 瑞士商赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| WO2015054659A1 (en) * | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN117534764A (zh) * | 2016-06-06 | 2024-02-09 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
-
2020
- 2020-07-02 EP EP20835081.9A patent/EP3994177A4/en active Pending
- 2020-07-02 MX MX2021015669A patent/MX2021015669A/es unknown
- 2020-07-02 WO PCT/AU2020/050690 patent/WO2021000018A1/en not_active Ceased
- 2020-07-02 KR KR1020227002845A patent/KR20220057517A/ko active Pending
- 2020-07-02 JP JP2021578269A patent/JP7678769B2/ja active Active
- 2020-07-02 BR BR112021026663A patent/BR112021026663A2/pt unknown
- 2020-07-02 CA CA3141471A patent/CA3141471A1/en active Pending
- 2020-07-02 AU AU2020299025A patent/AU2020299025A1/en active Pending
- 2020-07-02 MA MA056469A patent/MA56469A/fr unknown
- 2020-07-02 US US17/622,333 patent/US20220323619A1/en active Pending
- 2020-07-02 CN CN202080054212.1A patent/CN114555641A/zh active Pending
-
2021
- 2021-12-29 CL CL2021003563A patent/CL2021003563A1/es unknown
- 2021-12-30 IL IL289523A patent/IL289523A/en unknown
-
2025
- 2025-01-09 JP JP2025003479A patent/JP2025069166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025077045A5 (enExample) | ||
| JP2022540385A5 (enExample) | ||
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| JP2022540384A5 (enExample) | ||
| AU2025202469A1 (en) | Radiolabeling of polypeptides | |
| US20220323619A1 (en) | Antibodies for binding psma with reduced affinity for the neonatal fc receptor | |
| US11981741B2 (en) | Humanized anti-CD45 antibodies | |
| US20240342323A1 (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| AU2019234468B2 (en) | Bispecific binding agents and uses thereof | |
| CA3069140A1 (en) | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy | |
| JP7759348B2 (ja) | がんの治療のための抗ｂ７ｈ３抗体 | |
| WO2011011592A1 (en) | Methods for generating radioimmunoconjugates | |
| JP2009268470A (ja) | 抗体分子を用いての腫瘍脈管系の選択的標的化 | |
| CA3205707A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| CA3184226A1 (en) | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy | |
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies | |
| WO2022268225A1 (zh) | CD8α结合多肽及其用途 | |
| JP2021511068A (ja) | Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用 | |
| ES2541907T3 (es) | Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos. | |
| HK40066936A (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| TW202600607A (zh) | Ｄｄｌ３結合免疫接合物及其用途 | |
| JP2026515739A (ja) | Ｓｔｅａｐ２標的化化合物及びその使用 | |
| CA3228414A1 (en) | Anti-cd33 antibodies and uses thereof | |
| HK40066937A (en) | Antibodies for binding psma with reduced affinity for the neonatal fc receptor | |
| WO2011110490A1 (en) | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |